Lu lab is set up at 2022.04, every project in the lab is motivated by unmet clinical needs and aimed at advancing drug development.

Positioned at the intersection of immunology and oncobiology, we seek to unravel how T cells survive  within the tumor microenvironment—particularly during immune checkpoint blockade therapy. 

Our major research interests include:

1,Tumor cell-intrinsic pathways – Investigating how chromosomal instability and other tumor intrinsic mechanisms influence the survival of tumor-infiltrating T cells.

2,DNA-damaging therapies – Examining how radiation and chemotherapy reshape the tumor immune microenvironment.

3,Immune modulators – Defining the roles of key immune-related genes and cell subtypes in sustaining durable anti-tumor T cell responses.

4,Therapeutic strategies– Designing innovative tumor vaccines, antibody-based drugs, small molecule compound and immune cell therapies to enhance cancer immunotherapy.